ATROVENT HFA Drug Patent Profile
✉ Email this page to a colleague
When do Atrovent Hfa patents expire, and what generic alternatives are available?
Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has ten patent family members in nine countries.
The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atrovent Hfa
A generic version of ATROVENT HFA was approved as ipratropium bromide by RITEDOSE CORP on January 26th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATROVENT HFA?
- What are the global sales for ATROVENT HFA?
- What is Average Wholesale Price for ATROVENT HFA?
Summary for ATROVENT HFA
International Patents: | 10 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 14 |
Clinical Trials: | 47 |
Patent Applications: | 4,265 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ATROVENT HFA |
DailyMed Link: | ATROVENT HFA at DailyMed |
Recent Clinical Trials for ATROVENT HFA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hat Yai Medical Education Center | Phase 3 |
University of Nevada, Las Vegas | Phase 4 |
Ohio State University | Phase 4 |
Pharmacology for ATROVENT HFA
Drug Class | Anticholinergic |
Mechanism of Action | Cholinergic Antagonists |
Paragraph IV (Patent) Challenges for ATROVENT HFA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ATROVENT HFA | Inhalation Aerosol | ipratropium bromide | 0.21 mg/Inh | 021527 | 1 | 2023-12-29 |
US Patents and Regulatory Information for ATROVENT HFA
ATROVENT HFA is protected by one US patents.
Patents protecting ATROVENT HFA
Inhaler device
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATROVENT HFA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | ATROVENT HFA | ipratropium bromide | AEROSOL, METERED;INHALATION | 021527-001 | Nov 27, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ATROVENT HFA
See the table below for patents covering ATROVENT HFA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 68924540 | ⤷ Sign Up | |
Eurasian Patent Organization | 200101158 | ⤷ Sign Up | |
United Kingdom | 8828477 | ⤷ Sign Up | |
Japan | 2786493 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |